These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 16076691)

  • 1. Targeted drugs in metastatic colorectal cancer with special emphasis on guidelines for the use of bevacizumab and cetuximab: an Acta Oncologica expert report.
    Nygren P; Sørbye H; Osterlund P; Pfeiffer P
    Acta Oncol; 2005; 44(3):203-17. PubMed ID: 16076691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy in colorectal cancer.
    Rajpal S; Venook AP
    Clin Adv Hematol Oncol; 2006 Feb; 4(2):124-32. PubMed ID: 16728921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Antibody treatment in colorectal cancer--what the surgeon needs to know].
    Thalheimer A; Illert B; Reimer P; Bueter M; Thiede A; Gasser M; Fein M; Waaga-Gasser AM; Meyer D
    Zentralbl Chir; 2008 Apr; 133(2):101-6. PubMed ID: 18415895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted agents for adjuvant therapy of colon cancer.
    Saif MW
    Clin Colorectal Cancer; 2006 May; 6(1):46-51. PubMed ID: 16796791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic therapy for colon cancer.
    He AR; Marshall J
    Clin Adv Hematol Oncol; 2005 Jul; 3(7):555-61. PubMed ID: 16167038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms and targeting of colorectal cancer.
    Vanhoefer U
    Semin Oncol; 2005 Dec; 32(6 Suppl 8):7-10. PubMed ID: 16360005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current issues in the targeted therapy of advanced colorectal cancer.
    Knijn N; Tol J; Punt CJ
    Discov Med; 2010 Apr; 9(47):328-36. PubMed ID: 20423677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. First-line treatment of patients with metastatic colorectal cancer: an overview of recent data on chemotherapy plus targeted agents.
    Cercek A; Saltz LB
    Clin Colorectal Cancer; 2008 Dec; 7 Suppl 2():S47-51. PubMed ID: 19064406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The multidisciplinary management of gastrointestinal cancer. The integration of cytotoxics and biologicals in the treatment of metastatic colorectal cancer.
    Van Cutsem E; Geboes K
    Best Pract Res Clin Gastroenterol; 2007; 21(6):1089-108. PubMed ID: 18070705
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic therapy for advanced or metastatic colorectal cancer: National Comprehensive Cancer Network guidelines for combining anti-vascular endothelial growth factor and anti-epidermal growth factor receptor monoclonal antibodies with chemotherapy.
    Engstrom PF;
    Pharmacotherapy; 2008 Nov; 28(11 Pt 2):18S-22S. PubMed ID: 18980548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies: the foundation of therapy for colorectal cancer in the 21st century?
    Hoff PM; Ellis LM; Abbruzzese JL
    Oncology (Williston Park); 2004 May; 18(6):736-41; discussion 742, 745-6. PubMed ID: 15214593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antivascular endothelial growth factor monoclonal antibody therapy: a promising paradigm in colorectal cancer.
    Franson PJ; Lapka DV
    Clin J Oncol Nurs; 2005 Feb; 9(1):55-60. PubMed ID: 15751499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted biotherapy in metastatic colorectal carcinoma: Current practice.
    Cacheux W; Le Tourneau C; Baranger B; Mignot L; Mariani P
    J Visc Surg; 2011 Feb; 148(1):12-8. PubMed ID: 21277276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal antibodies in gastrointestinal cancers.
    Bronte G; Cicero G; Cusenza S; Galvano A; Musso E; Rizzo S; Sortino G; Roselli M; Bazan V; Fiorentino E; Russo A
    Expert Opin Biol Ther; 2013 Jun; 13(6):889-900. PubMed ID: 23441760
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cetuximab (Erbitux)].
    Shimoyama T
    Gan To Kagaku Ryoho; 2009 Jul; 36(7):1203-12. PubMed ID: 19620819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monoclonal antibodies in the treatment of colorectal cancer.
    Veronese ML; O'Dwyer PJ
    Eur J Cancer; 2004 Jun; 40(9):1292-301. PubMed ID: 15177487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacodynamics of DT-IgG, a dual-targeting antibody against VEGF-EGFR, in tumor xenografted mice.
    Hurwitz SJ; Zhang H; Yun S; Batuwangala TD; Steward M; Holmes SD; Rycroft D; Pan L; Tighiouart M; Shin HJ; Koenig L; Wang Y; Chen ZG; Shin DM
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):577-90. PubMed ID: 21913035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
    Wong SF
    Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update on novel therapeutic agents for cervical cancer.
    del Campo JM; Prat A; Gil-Moreno A; Pérez J; Parera M
    Gynecol Oncol; 2008 Sep; 110(3 Suppl 2):S72-6. PubMed ID: 18544460
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.